Neurocognitive function in head and neck cancer patients prior to treatment
Neurocognitive function in head and neck cancer patients prior to treatment
复制标题
DOI：
10.1007/s00520-010-1081-9
复制
发表时间：
2012-01-01
影响因子：
3.1
通讯作者：
Murphy, Barbara A.
中科院分区：
文献类型：
--
作者：
Bond, Stewart M.;Dietrich, Mary S.;Murphy, Barbara A.
神经认知障碍是癌症患者常见的临床重要问题，但很少有研究在头颈癌（HNC）患者中进行。我们的目的是（1）确定新诊断的HNC患者的基线神经认知功能障碍的患病率，（2）检查神经认知功能与自我报告的神经认知功能之间的关系，（3）探索神经认知功能与社会人口统计学，临床，症状困扰，70名患者接受了简短的神经心理学测试，并在开始治疗前完成了自我报告措施。在目前的队列中，7%的HNC患者在开始诱导化疗或同步放化疗之前，在神经心理学测试中表现出整体神经认知障碍。以下神经认知领域的损害更为常见：言语学习（36%），执行功能（32%），言语记忆（30%）和处理速度（27%）。神经认知表现与自我报告的神经认知功能无关。神经认知功能和其他身体或心理症状之间很少有显着的关联，但是，自我报告的神经认知功能和这些symptoms.Neurocognitive损害是常见的新诊断的HNC患者开始治疗前发现中等强度的协会。治疗前神经认知损害对治疗耐受性、治疗结果和治疗需求的影响是未来研究的重要领域。治疗前神经认知障碍的机制也需要探讨。
Neurocognitive impairment is a common and clinically important problem in patients with cancer, but few studies have been conducted in head and neck cancer (HNC) patients. Our aims were to (1) determine the prevalence of baseline neurocognitive impairment in patients with newly diagnosed HNC, (2) examine the relationships between neurocognitive performance and self-reported neurocognitive function, and (3) explore relationships between neurocognitive function and sociodemographic, clinical, symptom distress, and mood variables.Seventy patients underwent testing with a brief neuropsychological test battery and completed self-report measures before starting treatment.Forty-seven percent of HNC patients in the current cohort exhibited global neurocognitive impairment on neuropsychological testing prior to starting induction chemotherapy or concurrent chemoradiation. Impairment was more common in the following neurocognitive domains: verbal learning (36%), executive function (32%), verbal memory (30%), and processing speed (27%). Neurocognitive performance was not associated with self-reported neurocognitive function. Few significant associations were noted between neurocognitive performance and other physical or psychological symptoms; however, moderately strong associations were found between self-reported neurocognitive function and these symptoms.Neurocognitive impairment is common in patients with newly diagnosed HNC before starting treatment. The impact of pretreatment neurocognitive impairment on treatment tolerance, treatment outcomes, and caregiving needs are important areas for future research. Mechanisms of pretreatment neurocognitive impairment also need to be explored.